Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient

BACKGROUND: With the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS). In view of the high costs, actual needs of the drug, and increasing evidence in literature, aHUS patients can be treated accord...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Bouwmeester, Romy N., Ter Avest, Mendy, Wijnsma, Kioa L., Duineveld, Caroline, ter Heine, Rob, Volokhina, Elena B., Van Den Heuvel, Lambertus P. W. J., Wetzels, Jack F. M., van de Kar, Nicole C. A. J.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843372/
https://ncbi.nlm.nih.gov/pubmed/33519821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.612706
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars